Hotspots in the Commercialization of Minimally Invasive Interventional Medical Devices: Several Innovative Products Have Been Launched, Addressing Key Clinical Challenges
Release date:
2026-03-04 14:20
Since the beginning of 2026, China’s minimally invasive interventional medical device sector has experienced a surge in product launches, with the pace of market entry accelerating steadily. Several globally pioneering and domestically leading innovative products have successfully obtained approval through the National Medical Products Administration’s (NMPA) Special Review Procedure for Innovative Medical Devices, covering core therapeutic areas such as cardiovascular and neurointerventional medicine. These innovations precisely address unmet clinical needs and fill critical treatment gaps, underscoring China’s robust innovation capacity and dynamic growth in this field.
The successful implementation of this series of innovative achievements would not have been possible without the support of cutting-edge medical testing technologies. Xi’an Dewei Medical, a provider specializing in high-end medical testing equipment, specialized testing services, and comprehensive testing solutions, is playing a pivotal role in the R&D and testing of minimally invasive interventional medical devices.
In the field of cardiovascular intervention, on February 27, MicroPort® Melody, a subsidiary of Shanghai MicroPort Medical, received market approval for its FireSpear™/Huofeng™ piezoelectric intravascular ultrasound therapeutic system for coronary arteries. This represents a milestone breakthrough in the treatment of chronic total occlusion (CTO) of the coronary arteries, providing a completely new therapeutic solution for clinical practice. On the same day, the NMPA also approved the marketing of MicroPort Melody’s intravascular ultrasound therapeutic device and its single-use coronary intravascular ultrasound guidewire. Together, these three products synergistically strengthen MicroPort Medical’s product portfolio in the coronary intervention space.
Piezoelectric Intravascular Ultrasound Therapy System for Coronary Arteries (Image source: MicroPort’s official WeChat account)
The research, development, and testing validation of such high-end minimally invasive interventional devices are inseparable from a clinically relevant, precision testing environment.
Xi’an Dewei Medical specializes in developing tailored simulation models and testing solutions for medical device engineers. With extensive experience and technical expertise in medical simulation, test equipment, medical software development, and test system integration, Dewei Medical provides comprehensive turnkey testing solutions for minimally invasive interventional device companies and high-end research-oriented medical laboratories. Dewei’s simulation models are produced using 3D printing technology to achieve a 1:1 reproduction of human anatomical structures; its vascular models are crafted from a proprietary, highly transparent soft silicone material that accurately replicates human hemodynamics and vascular physiological characteristics. When paired with sensors, flow monitors, pressure transducers, and push-force testing devices, these models enable precise performance evaluation of minimally invasive interventional medical devices, providing reliable support for product R&D optimization and performance validation. This helps innovative devices expedite regulatory testing and clinical translation.
DeWei Medical Product Showcase
In addition to its minimally invasive product portfolio, on January 29, Shanghai MicroPort EP’s single-use intracardiac ultrasound imaging catheter received smooth approval, thereby enhancing the ancillary diagnostic and therapeutic system for cardiac intervention procedures, facilitating the precise and safe performance of complex surgeries, and earning clinical recognition.
China’s minimally invasive interventional medical device companies have now gained international recognition for their innovative capabilities. On February 27, Shanghai MicroPort HeartVascular’s Hector®/Tongtianji™ thoracic aortic multi-branch covered stent system was granted Breakthrough Device designation by the U.S. Food and Drug Administration. This product is indicated for the minimally invasive treatment of complex thoracic aortic lesions and is expected to accelerate its entry into international markets, enabling the “Chinese solution” to serve patients worldwide.
Hector Registered trademark /Tongtianji™ Thoracic Aortic Multi-Branch Covered Stent System
On the international market, the pace of innovation and product launch for minimally invasive interventional devices has also accelerated. In early March, the FDA approved DASI Simulations’ AI-powered 3D planning platform, which can accurately simulate cardiac intervention procedures and provide technical support for device R&D and preoperative rehearsal, marking the entry of minimally invasive interventional surgery into the “digital twin” era. Companies such as Dassault Systèmes are also stepping up their deployment of AI simulation technologies to enhance device design and optimize testing.
Meanwhile, DeWei Medical’s simulation testing solutions complement such digital technologies, further enhancing the R&D and testing framework for minimally invasive interventional devices. 。
Overall, during January–February 2026, China saw a flurry of approvals for several minimally invasive interventional medical devices, including single-use peripheral vascular thrombectomy catheters and self-expanding intraluminal aneurysm embolization devices, covering multiple niche segments and creating a pattern of diversified development across multiple fronts.
The rapid commercialization of these products has been made possible by companies’ R&D investments, collaboration between medical and engineering disciplines, and policy support from national regulatory authorities—such as the Special Review Procedure for Innovative Medical Devices and priority review—which have significantly shortened the review cycle and created broader opportunities for test-solution providers like Dewei Medical.
The successful launch of multiple minimally invasive interventional medical devices has not only addressed critical clinical treatment challenges and filled therapeutic gaps, but also propelled China’s industry in this field toward higher-end, precision-driven, and internationalized development. Looking ahead,
With ongoing technological advancements and the refinement of regulatory frameworks, an increasing number of innovative products will be brought to market. Xi’an Dewei Medical will continue to leverage its technological strengths, providing high-quality simulation models, testing equipment, and end-to-end solutions to offer comprehensive support to minimally invasive interventional device manufacturers, thereby helping China establish itself as a global hub for innovation in the field of minimally invasive interventional medical devices.
DeWei Medical Products Receive Positive Market Feedback
Keywords:
Medical devices,Medical simulation model,Minimally Invasive Intervention,Simulation testing,Medical Simulation,3D printing,Food and Drug Administration,Neurointerventional Vascular Model,Peripheral Intervention,Silicone vascular model
Other news
Request a quote
*Please keep your phone accessible—we'll reach out to you within 24 hours.
PARTNERSHIP
Partnership
Contact us
Address: Wangzuo Qujiang, 3269 Yanxiang Road, Yanta District, Xi'an City
Pre-sales Consultation
Request a quote
